Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bugat

Showing results (111-120 of 149) with videos related to

Pageof 15
Sort By:
American Journal of Clinical Oncology|January 1, 1988
Zoladex as primary therapy in advanced prostatic cancer. A French cooperative trialR Metz, M Namer, L Adenis, et al.
British Journal of Cancer|January 22, 2004
Factors affecting pharmacokinetic variability of oral topotecan: a population analysisF Léger, W J Loos, J Fourcade, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study GroupM F Avril, J Bonneterre, M Delaunay, et al.
Clinical Pharmacology and Therapeutics|March 1, 1992
Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicitiesP Canal, J Robert, M Ramon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 1999
A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancerM Friedlander, M J Millward, D Bell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1996
Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of CancerP Canal, C Gay, A Dezeuze, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2008
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junctionM Dank, J Zaluski, C Barone, et al.
Cancer Chemotherapy and Pharmacology|June 15, 2000
Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humansR Guimbaud, S Guichard, C Dusseau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility studyY Merrouche, J M Extra, D Abigerges, et al.
Pathologie-Biologie|November 1, 1992
[Intraperitoneal recombinant gamma interferon (RU 42369) efficacy in ovarian carcinomas. European BRM Study Group]J P Guastalla, E Pujade-Lauraine, N Colombo, et al.
Pageof 15

Showing results (111-120 of 149) with videos related to

Sort By:
Pageof 15
American Journal of Clinical Oncology|January 1, 1988
Zoladex as primary therapy in advanced prostatic cancer. A French cooperative trialR Metz, M Namer, L Adenis, et al.
British Journal of Cancer|January 22, 2004
Factors affecting pharmacokinetic variability of oral topotecan: a population analysisF Léger, W J Loos, J Fourcade, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study GroupM F Avril, J Bonneterre, M Delaunay, et al.
Clinical Pharmacology and Therapeutics|March 1, 1992
Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicitiesP Canal, J Robert, M Ramon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 1999
A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancerM Friedlander, M J Millward, D Bell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1996
Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of CancerP Canal, C Gay, A Dezeuze, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2008
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junctionM Dank, J Zaluski, C Barone, et al.
Cancer Chemotherapy and Pharmacology|June 15, 2000
Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humansR Guimbaud, S Guichard, C Dusseau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility studyY Merrouche, J M Extra, D Abigerges, et al.
Pathologie-Biologie|November 1, 1992
[Intraperitoneal recombinant gamma interferon (RU 42369) efficacy in ovarian carcinomas. European BRM Study Group]J P Guastalla, E Pujade-Lauraine, N Colombo, et al.
Pageof 15